IND Application Process

## What Is an IND

An Investigational New Drug (IND) application is the regulatory submission that requests FDA permission to administer an experimental drug to humans. No clinical trial may begin in the United States without an active IND. The IND becomes effective 30 calendar days after FDA receipt unless the agency places it on clinical hold.

The IND is not a single document but a living regulatory file that is continuously updated with new data throughout clinical development.

## IND Content Requirements

The IND contains three major sections as specified in 21 CFR 312:

**Section 1 - Chemistry, Manufacturing, and Controls (CMC)**: Drug substance (active ingredient) and drug product (finished dosage form) information including composition, manufacturing process, specifications, analytical methods, stability data, and container closure system. For Phase I, abbreviated CMC is acceptable; requirements increase as development progresses.

**Section 2 - Pharmacology and Toxicology**: All nonclinical data supporting safety for the proposed clinical trial. This includes pharmacology studies (mechanism of action, efficacy in disease models), pharmacokinetic/ADME studies, and toxicology studies (GLP general toxicity, genetic toxicology, safety pharmacology). An integrated summary written by a qualified expert interprets the nonclinical data in context of proposed human studies.

**Section 3 - Clinical Protocol and Investigator Information**: The Phase I clinical protocol including study design, dose escalation scheme, inclusion/exclusion criteria, endpoints, and stopping rules. Investigator brochure (IB) compiling all known drug information for clinical investigators. Form FDA 1572 (investigator commitment) and IRB approval documentation.

## The 30-Day Review

After FDA receives the IND, the assigned review division has 30 calendar days to evaluate the submission. If no clinical hold is issued within 30 days, the sponsor may initiate the clinical trial. FDA reviewers assess:

- Whether preclinical data adequately support the proposed dose and route
- Whether the clinical protocol design protects subject safety
- Whether the investigator qualifications are adequate
- Whether CMC information ensures a consistent, quality product

## Clinical Hold

FDA may issue a **full clinical hold** (no subjects may be enrolled) or **partial hold** (specific aspects restricted) if:

- Subjects would face unreasonable risk of illness or injury
- The IND does not contain sufficient information
- The protocol design is deficient for assessing safety
- The investigator brochure is misleading or incomplete

The sponsor must address all hold issues and receive written notification before resuming trials.

## IND Amendments and Reporting

After the IND is active, the sponsor must submit:

- **Protocol amendments**: New protocols or significant changes to existing ones
- **IND safety reports**: Serious and unexpected suspected adverse reactions within 15 days (7 days for fatal/life-threatening)
- **Annual reports**: Summary of clinical and nonclinical progress, safety data, and manufacturing changes
- **Information amendments**: New preclinical data, CMC changes, or other relevant information

## Types of IND

**Commercial IND**: Filed by companies intending to market the drug. Most common type.

**Research IND**: Filed by investigators for non-commercial research purposes.

**Emergency IND**: Allows use of an experimental drug in a life-threatening situation before formal IND submission. FDA must be notified within 15 days.

**Pre-IND meeting**: A Type B meeting with FDA to discuss the development plan and IND content before submission. Highly recommended, especially for novel mechanisms.

## Key Takeaways

- The IND becomes effective 30 days after submission unless FDA issues a clinical hold
- Three core sections: CMC, nonclinical pharmacology/toxicology, and clinical protocol
- Safety reporting obligations begin immediately and continue throughout the IND lifecycle
- Pre-IND meetings with FDA reduce submission deficiencies and clinical hold risk